Cargando…

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer

BACKGROUND: Early-onset or hereditary ovarian cancer is mostly associated with BRCA1 or BRCA2 mutations. Mismatch repair genes sequence alteration frequently cause colorectal cancer, and, in less extent, other tumors, such as ovarian cancer. Subjects with personal and/or family history suggestive fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pensabene, Matilde, Condello, Caterina, Carlomagno, Chiara, De Placido, Sabino, Liccardo, Raffaella, Duraturo, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011803/
https://www.ncbi.nlm.nih.gov/pubmed/27602174
http://dx.doi.org/10.1186/s13053-016-0054-5
_version_ 1782451897049808896
author Pensabene, Matilde
Condello, Caterina
Carlomagno, Chiara
De Placido, Sabino
Liccardo, Raffaella
Duraturo, Francesca
author_facet Pensabene, Matilde
Condello, Caterina
Carlomagno, Chiara
De Placido, Sabino
Liccardo, Raffaella
Duraturo, Francesca
author_sort Pensabene, Matilde
collection PubMed
description BACKGROUND: Early-onset or hereditary ovarian cancer is mostly associated with BRCA1 or BRCA2 mutations. Mismatch repair genes sequence alteration frequently cause colorectal cancer, and, in less extent, other tumors, such as ovarian cancer. Subjects with personal and/or family history suggestive for hereditary cancer should be addressed to cancer genetic counseling, aimed to the identification, definition and management of hereditary cancer syndrome, by a multidisciplinary approach. CASE PRESENTATION: A woman with a very early onset epithelial ovarian cancer underwent to cancer genetic counseling and genetic testing. Pedigree analysis suggested a clinical diagnosis of Lynch II syndrome, according to the Amsterdam criteria. The MMRpro model showed a cumulative risk of mutation of 50.3 %, thus, genetic testing was offered to the patient. Two germ-line mutations have been identified in exon 11 of MSH2 gene: c.1706A > T (p.Glu569Val) and c.1711G > T (p.Glu571*). Both DNA alterations were novel mutations not yet described in literature. The first is a missense mutation that is to be considered an unclassified variant; the second is nonsense mutation that created a premature stop codon resulting in a truncated not functioning protein. Both genetic alterations were found in the patients’ father DNA. CONCLUSIONS: The present report finds out two unpublished sequence alterations in exon 11 of the MSH2 gene, one on which can be considered causative of Lynch phenotype. Moreover, it stresses the importance of the multidisciplinary onco-genetic counselling in order to correctly frame the hereditary syndrome, suggest the right genetic test, and offer the most appropriate management of the cancer risk for the patients and her family members.
format Online
Article
Text
id pubmed-5011803
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50118032016-09-07 Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer Pensabene, Matilde Condello, Caterina Carlomagno, Chiara De Placido, Sabino Liccardo, Raffaella Duraturo, Francesca Hered Cancer Clin Pract Case Report BACKGROUND: Early-onset or hereditary ovarian cancer is mostly associated with BRCA1 or BRCA2 mutations. Mismatch repair genes sequence alteration frequently cause colorectal cancer, and, in less extent, other tumors, such as ovarian cancer. Subjects with personal and/or family history suggestive for hereditary cancer should be addressed to cancer genetic counseling, aimed to the identification, definition and management of hereditary cancer syndrome, by a multidisciplinary approach. CASE PRESENTATION: A woman with a very early onset epithelial ovarian cancer underwent to cancer genetic counseling and genetic testing. Pedigree analysis suggested a clinical diagnosis of Lynch II syndrome, according to the Amsterdam criteria. The MMRpro model showed a cumulative risk of mutation of 50.3 %, thus, genetic testing was offered to the patient. Two germ-line mutations have been identified in exon 11 of MSH2 gene: c.1706A > T (p.Glu569Val) and c.1711G > T (p.Glu571*). Both DNA alterations were novel mutations not yet described in literature. The first is a missense mutation that is to be considered an unclassified variant; the second is nonsense mutation that created a premature stop codon resulting in a truncated not functioning protein. Both genetic alterations were found in the patients’ father DNA. CONCLUSIONS: The present report finds out two unpublished sequence alterations in exon 11 of the MSH2 gene, one on which can be considered causative of Lynch phenotype. Moreover, it stresses the importance of the multidisciplinary onco-genetic counselling in order to correctly frame the hereditary syndrome, suggest the right genetic test, and offer the most appropriate management of the cancer risk for the patients and her family members. BioMed Central 2016-09-06 /pmc/articles/PMC5011803/ /pubmed/27602174 http://dx.doi.org/10.1186/s13053-016-0054-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Pensabene, Matilde
Condello, Caterina
Carlomagno, Chiara
De Placido, Sabino
Liccardo, Raffaella
Duraturo, Francesca
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title_full Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title_fullStr Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title_full_unstemmed Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title_short Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
title_sort two novel sequence variants in msh2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011803/
https://www.ncbi.nlm.nih.gov/pubmed/27602174
http://dx.doi.org/10.1186/s13053-016-0054-5
work_keys_str_mv AT pensabenematilde twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer
AT condellocaterina twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer
AT carlomagnochiara twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer
AT deplacidosabino twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer
AT liccardoraffaella twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer
AT duraturofrancesca twonovelsequencevariantsinmsh2geneinapatientwhounderwentcancergeneticcounselingforaveryearlyonsetepithelialovariancancer